These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 18656807)

  • 21. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy.
    Kumar A; Choudhary G; Antonio C; Just V; Jain A; Heaney L; Papp MA
    Am Heart J; 2001 Sep; 142(3):512-5. PubMed ID: 11526366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis.
    Bell DS; Lukas MA; Holdbrook FK; Fowler MB
    Curr Med Res Opin; 2006 Feb; 22(2):287-96. PubMed ID: 16466600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
    Tatli E; Kurum T
    Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
    Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
    Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
    DasGupta P; Broadhurst P; Lahiri A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone.
    Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J
    Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure).
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB
    Am J Cardiol; 2008 Dec; 102(11):1524-9. PubMed ID: 19026308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
    Ogihara T; Ikeda M; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S108-12. PubMed ID: 2454355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol.
    Fraga R; Franco FG; Roveda F; de Matos LN; Braga AM; Rondon MU; Rotta DR; Brum PC; Barretto AC; Middlekauff HR; Negrão CE
    Eur J Heart Fail; 2007; 9(6-7):630-6. PubMed ID: 17475552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.
    Massie BM; Nelson JJ; Lukas MA; Greenberg B; Fowler MB; Gilbert EM; Abraham WT; Lottes SR; Franciosa JA;
    Am J Cardiol; 2007 May; 99(9):1263-8. PubMed ID: 17478155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial).
    Rickli H; Steiner S; Müller K; Hess OM
    Eur J Heart Fail; 2004 Oct; 6(6):761-8. PubMed ID: 15542414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection.
    Chin BS; Gibbs CR; Blann AD; Lip GY
    Clin Sci (Lond); 2003 Oct; 105(4):507-12. PubMed ID: 12841846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure.
    Del Sindaco D; Pulignano G; Cioffi G; Tarantini L; Di Lenarda A; De Feo S; Opasich C; Minardi G; Giovannini E; Leggio F
    J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):675-82. PubMed ID: 17700396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carvedilol in heart failure: the MOCHA trial.
    Osterziel KJ
    Circulation; 1997 Oct; 96(8):2742; author reply 2743-4. PubMed ID: 9355927
    [No Abstract]   [Full Text] [Related]  

  • 35. Carvedilol use in heart failure.
    Neal CP; Kendrach MG
    Ann Pharmacother; 1998 Mar; 32(3):376-81. PubMed ID: 9533068
    [No Abstract]   [Full Text] [Related]  

  • 36. Carvedilol suppresses intractable hiccups.
    Stueber D; Swartz CM
    J Am Board Fam Med; 2006; 19(4):418-21. PubMed ID: 16809659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. We should not hesitate to use beta-blockers for systolic heart failure with concomitant renal dysfunction.
    Matsuda N
    Circ J; 2010 Aug; 74(8):1526-7. PubMed ID: 20647630
    [No Abstract]   [Full Text] [Related]  

  • 38. [Carvedilol therapy in pediatric patients with Takayasu's arteritis complicated with congestive heart failure: a case report].
    Wu XY; Song HM; Wei M
    Zhonghua Er Ke Za Zhi; 2009 Apr; 47(4):315-6. PubMed ID: 19555579
    [No Abstract]   [Full Text] [Related]  

  • 39. Carvedilol for anthracycline cardiomyopathy prevention.
    Florenzano F; Salman P
    J Am Coll Cardiol; 2007 May; 49(21):2142; author reply 2142-3. PubMed ID: 17531665
    [No Abstract]   [Full Text] [Related]  

  • 40. No gender survival difference in a population of patients with chronic heart failure related to left ventricular systolic dysfunction and receiving optimal medical therapy.
    de Groote P; Lamblin N; Mouquet F; Bauters C
    Arch Cardiovasc Dis; 2008 Apr; 101(4):242-8. PubMed ID: 18654099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.